ChromaCode
Carlsbad, US · Founded 2012 · Delaware corporation · 9 known investors
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical Devices
Founders & leadership
PF
Paul FlookExecutive
GJ
Gregory J. GoschExecutive
LR
Lynne RollinsExecutive
AR
Aditya RajagopalNamed on SEC filing
AS
Axel SchererNamed on SEC filing
Board
JK
JC
AG
Alexander G. DickinsonBoard director
Investors · 9
Adjuvant CapitalNew York · $10M – $25M
Global BrainTokyo · $100K – $184M
Moore Venture PartnersSan Diego
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Windham Capital PartnersNew York · $1M – $5M
Domain AssociatesreportedPrinceton · $200K – $15M
Domain PartnersreportedPrinceton
Northpond VenturesreportedBethesda · $100K – $5M
Vensana Capitalreported · 2 sourcesMinneapolisvia Justin Klein · board
Reported raises · per SEC filings
Form D private placements$94.2M disclosed across 5 rounds · 2017–2025
▶$3.8MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
▶$3.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aditya RajagopalDirector
- Paul FlookExecutive Officer, Director
- Justin KleinDirector
- Offering amount
- $5M
- Amount sold
- $3.8M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38MraisedFeb 2023 · 16 investors · BiotechnologyRule 506(b)
▶$38MraisedFeb 2023 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark McDonoughExecutive Officer, Director
- Justin KleinDirector
- Pat SmerkersDirector
- Alexander G. DickinsonDirector
- Kevin O'BoyleDirector
- Carol GallagherDirector
- Aditya RajagopalDirector
- Jenny YipDirector
- Offering amount
- $43M
- Amount sold
- $38M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38.6MraisedDec 2020 · 17 investors · BiotechnologyRule 506(b)
▶$38.6MraisedDec 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jenny YipDirector
- Lynne RollinsExecutive Officer
- Pat SmerkersDirector
- Carol GallagherDirector
- James C. BlairDirector
- Alexander G. DickinsonDirector
- Aditya RajagopalDirector
- Gregory J. GoschExecutive Officer, Director
- Offering amount
- $41.2M
- Amount sold
- $38.6M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedApr 2019 · 6 investors · BiotechnologyRule 506(b)
▶$1.8MraisedApr 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James C. BlairDirector
- Carol GallagherDirector
- Alexander G. DickinsonDirector
- Gregory J. GoschExecutive Officer, Director
- Aditya RajagopalDirector
- Lynne RollinsExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $1.8M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedApr 2017 · 9 investors · Other Health CareRule 506(b)
▶$12MraisedApr 2017 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James C. BlairDirector
- Gregory J. GoschExecutive Officer, Director
- Peter Justin KleinDirector
- Axel SchererDirector
- Alexander G. DickinsonDirector
- Lynne RollinsExecutive Officer
- Offering amount
- $12.1M
- Amount sold
- $12M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapTranscode Therapeutics5 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
JUMPCODE Genomics4 shared keywordsJumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
Genomeweb3 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.
Companies competing with ChromaCode for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ChromaCode do?
- ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
- Who are ChromaCode's investors?
- ChromaCode's investors include Adjuvant Capital, Global Brain, Moore Venture Partners, New Enterprise Associates (NEA), Windham Capital Partners, Domain Associates, Domain Partners, Northpond Ventures and 1 more.
- How much funding has ChromaCode raised?
- ChromaCode has disclosed $94.2M raised across 5 rounds.
- Where is ChromaCode headquartered?
- ChromaCode is headquartered in Carlsbad, US.